BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mirzaei S, Paskeh MDA, Saghari Y, Zarrabi A, Hamblin MR, Entezari M, Hashemi M, Aref AR, Hushmandi K, Kumar AP, Rabiee N, Ashrafizadeh M, Samarghandian S. Transforming growth factor-beta (TGF-β) in prostate cancer: A dual function mediator? Int J Biol Macromol 2022:S0141-8130(22)00340-3. [PMID: 35202639 DOI: 10.1016/j.ijbiomac.2022.02.094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Pellegrino M, Ricci E, Ceraldi R, Nigro A, Bonofiglio D, Lanzino M, Morelli C. From HDAC to Voltage-Gated Ion Channels: What's Next? The Long Road of Antiepileptic Drugs Repositioning in Cancer. Cancers (Basel) 2022;14:4401. [PMID: 36139561 DOI: 10.3390/cancers14184401] [Reference Citation Analysis]
2 Shi X, Niu Y, Yang Y, Wang N, Yuan M, Yang C, Dong A, Zhu H, Jia X, Xu Q. Identification of a Prognostic Model Based on Immune Cell Signatures in Clear Cell Renal Cell Carcinoma. Oxidative Medicine and Cellular Longevity 2022;2022:1-16. [DOI: 10.1155/2022/1727575] [Reference Citation Analysis]
3 Chandran E, Meininger L, Karzai F, Madan RA. Signaling new therapeutic opportunities: cytokines in prostate cancer. Expert Opin Biol Ther 2022. [PMID: 35930001 DOI: 10.1080/14712598.2022.2108701] [Reference Citation Analysis]
4 Li L, Yu J, Cheng S, Peng Z, Ben-David Y, Luo H. Transcription factor Fli-1 as a new target for antitumor drug development. Int J Biol Macromol 2022;209:1155-68. [PMID: 35447268 DOI: 10.1016/j.ijbiomac.2022.04.076] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]